Skip to main content
Erschienen in: Langenbeck's Archives of Surgery 3/2014

01.03.2014 | Original Article

Prognostic factors for primary gastrointestinal stromal tumours: are they the same in the multidisciplinary treatment era?

verfasst von: Ferdinando C. M. Cananzi, Bruno Lorenzi, Ajay Belgaumkar, Charlotte Benson, Ian Judson, Satvinder Mudan

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumour of the gastrointestinal tract. The introduction of tyrosine kinase inhibitors (TKIs) has lead to increasing use of combination of medical and surgical therapy. The aim of this study was to look at outcomes from a series of surgically treated GISTs and determine prognostic factors in the context of multimodal therapy.

Methods

We analysed 104 single surgeon’s patients with GIST. End points of the study were disease-specific survival (DSS), disease-free survival (DFS) and post-operative complications.

Results

Three- and 5-year DSS rates were 96.7 and 94.6 %. On univariate analysis, clear resection margins were predictive of DSS. Patients with R2 resection had a worse prognosis (3-year DSS rate of 83.3 %; 5-year DSS rate of 62.5 %) compared to patients with R0 (3-year DSS rate of 98 %; 5-year DSS rate of 98 %) or R1 resection (3-year DSS rate of 100 %; 5-year DSS rate of 100 %) (R0 vs R1 vs. R2 p = 0.001). Pre-operative factors associated with R2 resection were clinical metastatic disease (p < 0.001), non-gastric tumour site (p = 0.002) and large tumour diameter (p = 0.031). Three- and 5-year DFS rates were 65.5 and 59.8 %. Serosal perforation (p = 0.013) and mitotic rate (p = 0.05) were found to be independently predictive of increased DFS. The presence of serosal perforation was associated with tumour site (p = 0.018), mitotic rate (p = 0.035), tumour diameter (p < 0.001), growth pattern (p = 0.007) and age (p = 0.040).

Conclusions

In the multidisciplinary management of GIST, serosal perforation may represent an additional predictor of recurrence along with mitotic rate. Complete macroscopic surgical resection is the most reliable prognostic factor, and an aggressive surgical approach should be advocated.
Literatur
1.
Zurück zum Zitat Fletcher CD, Berman JJ, Corless C, Gorstein F et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459–465PubMedCrossRef Fletcher CD, Berman JJ, Corless C, Gorstein F et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459–465PubMedCrossRef
2.
Zurück zum Zitat Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580PubMedCrossRef Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580PubMedCrossRef
3.
Zurück zum Zitat Kindblom LG, Remotti HE, Aldenborg F et al (1998) Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259–1269PubMedCentralPubMed Kindblom LG, Remotti HE, Aldenborg F et al (1998) Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259–1269PubMedCentralPubMed
4.
Zurück zum Zitat Sarlomo-Rikala M, Kovatich AJ, Barusevicius A et al (1998) CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 11:728–734PubMed Sarlomo-Rikala M, Kovatich AJ, Barusevicius A et al (1998) CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 11:728–734PubMed
5.
Zurück zum Zitat de Silva CM, Reid R (2003) Gastrointestinal stromal tumors (GIST): c-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res 9:13–19PubMedCrossRef de Silva CM, Reid R (2003) Gastrointestinal stromal tumors (GIST): c-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res 9:13–19PubMedCrossRef
6.
Zurück zum Zitat DeMatteo RP, Lewis JJ, Leung D et al (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51–58PubMedCentralPubMedCrossRef DeMatteo RP, Lewis JJ, Leung D et al (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51–58PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Ng EH, Pollock RE, Romsdahl MM (1992) Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 9:1334–1341CrossRef Ng EH, Pollock RE, Romsdahl MM (1992) Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 9:1334–1341CrossRef
8.
Zurück zum Zitat Ng EH, Pollock RE, Munsell MF et al (1992) Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 215:68–77PubMedCentralPubMedCrossRef Ng EH, Pollock RE, Munsell MF et al (1992) Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 215:68–77PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Mudan SS, Conlon KC, Woodruff JM et al (2000) Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 88:66–74PubMedCrossRef Mudan SS, Conlon KC, Woodruff JM et al (2000) Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 88:66–74PubMedCrossRef
10.
Zurück zum Zitat Clary BM, DeMatteo RP, Lewis JJ et al (2001) Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol 8:290–299PubMedCrossRef Clary BM, DeMatteo RP, Lewis JJ et al (2001) Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol 8:290–299PubMedCrossRef
11.
Zurück zum Zitat Le Cesne A, Judson I, Crowther D et al (2000) Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European organization for research and treatment of cancer/soft tissue and bone sarcoma group. J Clin Oncol 18:2676–2684PubMed Le Cesne A, Judson I, Crowther D et al (2000) Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European organization for research and treatment of cancer/soft tissue and bone sarcoma group. J Clin Oncol 18:2676–2684PubMed
12.
Zurück zum Zitat Nielsen OS, Judson I, van Hoesel Q et al (2000) Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 36:61–67PubMedCrossRef Nielsen OS, Judson I, van Hoesel Q et al (2000) Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 36:61–67PubMedCrossRef
13.
Zurück zum Zitat Patel SR, Gandhi V, Jenkins J et al (2001) Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19:3483–3489PubMed Patel SR, Gandhi V, Jenkins J et al (2001) Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19:3483–3489PubMed
14.
Zurück zum Zitat DeMatteo RP, Heinrich MC, El-Rifai WM et al (2002) Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 33:466–477PubMedCrossRef DeMatteo RP, Heinrich MC, El-Rifai WM et al (2002) Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 33:466–477PubMedCrossRef
15.
Zurück zum Zitat Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480PubMedCrossRef Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480PubMedCrossRef
16.
Zurück zum Zitat Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338PubMedCrossRef Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338PubMedCrossRef
17.
Zurück zum Zitat Debiec-Rychter M, Dumez H, Judson I et al (2004) Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40:689–695PubMedCrossRef Debiec-Rychter M, Dumez H, Judson I et al (2004) Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40:689–695PubMedCrossRef
18.
Zurück zum Zitat Antonescu CR, Besmer P, Guo T et al (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11:4182–4190PubMedCrossRef Antonescu CR, Besmer P, Guo T et al (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11:4182–4190PubMedCrossRef
19.
Zurück zum Zitat Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342–4349PubMedCrossRef Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342–4349PubMedCrossRef
21.
Zurück zum Zitat Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620–625PubMedCrossRef Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620–625PubMedCrossRef
22.
Zurück zum Zitat Gramza AW, Corless CL, Heinrich MC (2009) Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res 15:7510–7518PubMedCrossRef Gramza AW, Corless CL, Heinrich MC (2009) Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res 15:7510–7518PubMedCrossRef
23.
Zurück zum Zitat George S, Wang Q, Heinrich MC et al (2012) Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumour after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol 30:2401–2407PubMedCentralPubMedCrossRef George S, Wang Q, Heinrich MC et al (2012) Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumour after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol 30:2401–2407PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat DeMatteo RP, Ballman KV, Antonescu CR et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373:1097–1104PubMedCentralPubMedCrossRef DeMatteo RP, Ballman KV, Antonescu CR et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373:1097–1104PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Joensuu H, Eriksson M, Sundby Hall K et al (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307:1265–1272PubMedCrossRef Joensuu H, Eriksson M, Sundby Hall K et al (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307:1265–1272PubMedCrossRef
26.
Zurück zum Zitat Andtbacka RH, Ng CS, Scaife CL et al (2007) Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 14:14–24PubMedCrossRef Andtbacka RH, Ng CS, Scaife CL et al (2007) Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 14:14–24PubMedCrossRef
27.
Zurück zum Zitat Gronchi A, Fiore M, Miselli F et al (2007) Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 245:341–346PubMedCentralPubMedCrossRef Gronchi A, Fiore M, Miselli F et al (2007) Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 245:341–346PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Shrikhande SV, Marda SS, Suradkar K et al (2012) Gastrointestinal stromal tumors: case series of 29 patients defining the role of imatinib prior to surgery. World J Surg 36:864–871PubMedCrossRef Shrikhande SV, Marda SS, Suradkar K et al (2012) Gastrointestinal stromal tumors: case series of 29 patients defining the role of imatinib prior to surgery. World J Surg 36:864–871PubMedCrossRef
29.
Zurück zum Zitat National Comprehensive Cancer Network (2009) Soft tissue sarcoma. In: NCCN clinical practice guidelines in oncology. http://www.nccn.org. Accessed June 2012 National Comprehensive Cancer Network (2009) Soft tissue sarcoma. In: NCCN clinical practice guidelines in oncology. http://​www.​nccn.​org. Accessed June 2012
30.
Zurück zum Zitat McCarter MD, Antonescu CR, Ballman KV et al (2012) Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. J Am Coll Surg 215:53–59PubMedCentralPubMedCrossRef McCarter MD, Antonescu CR, Ballman KV et al (2012) Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. J Am Coll Surg 215:53–59PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Nikfarjam M, Kimchi E, Shereef S et al (2008) Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy. J Gastrointest Surg 12:2023–2031PubMedCrossRef Nikfarjam M, Kimchi E, Shereef S et al (2008) Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy. J Gastrointest Surg 12:2023–2031PubMedCrossRef
32.
Zurück zum Zitat Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef
33.
Zurück zum Zitat Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759PubMedCrossRef Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759PubMedCrossRef
34.
Zurück zum Zitat Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23:70–83PubMedCrossRef Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23:70–83PubMedCrossRef
35.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213PubMedCentralPubMedCrossRef Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213PubMedCentralPubMedCrossRef
36.
Zurück zum Zitat Joensuu H, Vehtari A, Riihimäki J et al (2012) Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 13:265–274PubMedCrossRef Joensuu H, Vehtari A, Riihimäki J et al (2012) Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 13:265–274PubMedCrossRef
37.
Zurück zum Zitat Wang D, Zhang Q, Blanke CD et al (2012) Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol 19:1074–1080PubMedCentralPubMedCrossRef Wang D, Zhang Q, Blanke CD et al (2012) Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol 19:1074–1080PubMedCentralPubMedCrossRef
38.
Zurück zum Zitat DeMatteo RP, Maki RG, Singer S et al (2007) Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 245:347–352PubMedCentralPubMedCrossRef DeMatteo RP, Maki RG, Singer S et al (2007) Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 245:347–352PubMedCentralPubMedCrossRef
39.
Zurück zum Zitat Cananzi FC, Judson I, Lorenzi B et al (2013) Multidisciplinary care of gastrointestinal stromal tumour: a review and a proposal for a pre-treatment classification. Eur J Surg Oncol 39:1171–1178PubMedCrossRef Cananzi FC, Judson I, Lorenzi B et al (2013) Multidisciplinary care of gastrointestinal stromal tumour: a review and a proposal for a pre-treatment classification. Eur J Surg Oncol 39:1171–1178PubMedCrossRef
40.
Zurück zum Zitat Rutkowski P, Gronchi A, Hohenberger P et al (2013) Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol 20:2937–2943PubMedCrossRef Rutkowski P, Gronchi A, Hohenberger P et al (2013) Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol 20:2937–2943PubMedCrossRef
41.
Zurück zum Zitat The ESMO/European Sarcoma Network Working Group (2012) Gastrointestinal stromal tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii49–vii55 The ESMO/European Sarcoma Network Working Group (2012) Gastrointestinal stromal tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii49–vii55
42.
Zurück zum Zitat Pisters PW, Leung DH, Woodruff J et al (1996) Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 14:1679–1689PubMed Pisters PW, Leung DH, Woodruff J et al (1996) Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 14:1679–1689PubMed
43.
Zurück zum Zitat Stojadinovic A, Leung DH, Hoos A et al (2002) Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg 235:424–434PubMedCentralPubMedCrossRef Stojadinovic A, Leung DH, Hoos A et al (2002) Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg 235:424–434PubMedCentralPubMedCrossRef
44.
Zurück zum Zitat Pierie JP, Choudry U, Muzikansky A et al (2001) The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 136:383–389PubMedCrossRef Pierie JP, Choudry U, Muzikansky A et al (2001) The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 136:383–389PubMedCrossRef
45.
Zurück zum Zitat Gouveia AM, Pimenta AP, Capelinha AF et al (2008) Surgical margin status and prognosis of gastrointestinal stromal tumor. World J Surg 32:2375–2382PubMedCrossRef Gouveia AM, Pimenta AP, Capelinha AF et al (2008) Surgical margin status and prognosis of gastrointestinal stromal tumor. World J Surg 32:2375–2382PubMedCrossRef
46.
Zurück zum Zitat Judson I (2010) Targeted therapies in soft tissue sarcomas. Ann Oncol 21:277–280CrossRef Judson I (2010) Targeted therapies in soft tissue sarcomas. Ann Oncol 21:277–280CrossRef
47.
Zurück zum Zitat Italiano A, Cioffi A, Coco P et al (2012) Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. Ann Surg Oncol 19:1551–1559PubMedCrossRef Italiano A, Cioffi A, Coco P et al (2012) Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. Ann Surg Oncol 19:1551–1559PubMedCrossRef
48.
Zurück zum Zitat Langer C, Gunawan B, Schüler P et al (2003) Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 90:332–339PubMedCrossRef Langer C, Gunawan B, Schüler P et al (2003) Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 90:332–339PubMedCrossRef
49.
Zurück zum Zitat Unalp HR, Derici H, Kamer E et al (2009) Gastrointestinal stromal tumours: outcomes of surgical management and analysis of prognostic variables. Can J Surg 52:31–38PubMedCentralPubMed Unalp HR, Derici H, Kamer E et al (2009) Gastrointestinal stromal tumours: outcomes of surgical management and analysis of prognostic variables. Can J Surg 52:31–38PubMedCentralPubMed
50.
Zurück zum Zitat Trovik CS (2001) Local recurrence of soft tissue sarcoma. A Scandinavian Sarcoma Group project. Acta Orthop Scand Suppl 72:1–31PubMedCrossRef Trovik CS (2001) Local recurrence of soft tissue sarcoma. A Scandinavian Sarcoma Group project. Acta Orthop Scand Suppl 72:1–31PubMedCrossRef
51.
Zurück zum Zitat Keun Park C, Lee EJ, Kim M et al (2008) Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy. Ann Surg 247:1011–1018PubMedCrossRef Keun Park C, Lee EJ, Kim M et al (2008) Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy. Ann Surg 247:1011–1018PubMedCrossRef
52.
Zurück zum Zitat Dematteo RP, Gold JS, Saran L et al (2008) Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 112:608–615PubMedCrossRef Dematteo RP, Gold JS, Saran L et al (2008) Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 112:608–615PubMedCrossRef
53.
Zurück zum Zitat Joensuu H (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39:1411–1419PubMedCrossRef Joensuu H (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39:1411–1419PubMedCrossRef
54.
Zurück zum Zitat Gold JS, Gönen M, Gutiérrez A et al (2009) Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 10:1045–1052PubMedCentralPubMedCrossRef Gold JS, Gönen M, Gutiérrez A et al (2009) Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 10:1045–1052PubMedCentralPubMedCrossRef
55.
Zurück zum Zitat Wardelmann E, Büttner R, Merkelbach-Bruse S et al (2007) Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy. Virchows Arch 451:743–749PubMedCrossRef Wardelmann E, Büttner R, Merkelbach-Bruse S et al (2007) Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy. Virchows Arch 451:743–749PubMedCrossRef
56.
Zurück zum Zitat Hohenberger P, Ronellenfitsch U, Oladeji O et al (2010) Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 97:1854–1859PubMedCrossRef Hohenberger P, Ronellenfitsch U, Oladeji O et al (2010) Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 97:1854–1859PubMedCrossRef
57.
Zurück zum Zitat Rutkowski P, Nowecki ZI, Michej W et al (2007) Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol 14:2018–2027PubMedCrossRef Rutkowski P, Nowecki ZI, Michej W et al (2007) Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol 14:2018–2027PubMedCrossRef
58.
Zurück zum Zitat Bucher P, Egger JF, Gervaz P et al (2006) An audit of surgical management of gastrointestinal stromal tumours (GIST). Eur J Surg Oncol 32:310–314PubMedCrossRef Bucher P, Egger JF, Gervaz P et al (2006) An audit of surgical management of gastrointestinal stromal tumours (GIST). Eur J Surg Oncol 32:310–314PubMedCrossRef
59.
Zurück zum Zitat Vallböhmer D, Marcus HE, Baldus SE et al (2008) Serosal penetration is an important prognostic factor for gastrointestinal stromal tumors. Oncol Rep 20:779–783PubMed Vallböhmer D, Marcus HE, Baldus SE et al (2008) Serosal penetration is an important prognostic factor for gastrointestinal stromal tumors. Oncol Rep 20:779–783PubMed
60.
Zurück zum Zitat Agaimy A, Vassos N, Wunsch PH et al (2012) Impact of serosal involvement/extramural growth on the risk of synchronous and metachronous peritoneal spread in gastrointestinal stromal tumors: proposal for a macroscopic classification of GIST. Int J Clin Exp Pathol 5:12–22PubMedCentralPubMed Agaimy A, Vassos N, Wunsch PH et al (2012) Impact of serosal involvement/extramural growth on the risk of synchronous and metachronous peritoneal spread in gastrointestinal stromal tumors: proposal for a macroscopic classification of GIST. Int J Clin Exp Pathol 5:12–22PubMedCentralPubMed
Metadaten
Titel
Prognostic factors for primary gastrointestinal stromal tumours: are they the same in the multidisciplinary treatment era?
verfasst von
Ferdinando C. M. Cananzi
Bruno Lorenzi
Ajay Belgaumkar
Charlotte Benson
Ian Judson
Satvinder Mudan
Publikationsdatum
01.03.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 3/2014
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-014-1160-3

Weitere Artikel der Ausgabe 3/2014

Langenbeck's Archives of Surgery 3/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.